LOGIN  |  REGISTER

Latest Medical Device Stock News

Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting

June 21
Last Trade: 4.63 -0.04 -0.86

91% of Venous Ulcer Patients Evaluated at One Year Have Either Fully Healed Ulcers or Ulcers That Have Improved 100% of Venous Ulcers with a Duration of One Year or Less Prior to VenoValve Surgery Have Fully Healed 89% of Venous Ulcers with a Duration of More Than One Year Prior to VenoValve Surgery Have Fully Healed or Improved No Ulcer Recurrences Company on Track to File Application Seeking VenoValve FDA Approval in Q4...Read more


Therma Bright Closes Second & Final Tranche of Fully Subscribed Non-Brokered Private Placement

June 21
Last Trade: 0.02 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it has completed the second and final tranche ("Final Tranche") of its previously announced $1,000,0000 non-brokered private placement (the "Offering"). Under...Read more


NeuroOne Medical Technologies Granted Approval of ICD-10 Procedure Code for sEEG RF Ablation

June 20
Last Trade: 0.82 -0.01 -1.25

ICD-10-PCS code for first to market, FDA-cleared thin-film, sEEG-guided RF ablation system effective October 1, 2024 Specific procedure code positions OneRF™ Ablation System for broader adoption and awareness throughout the healthcare system EDEN PRAIRIE, Minn., June 20, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving...Read more


ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial

June 20
Last Trade: 5.62 0.08 1.44

SOLANA BEACH, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner Aspen Neuroscience, Inc. on use of the ClearPoint Neuro Navigation System to transplant dopaminergic neuron precursor cells (DANPCs) for all enrolled patients with Parkinson’s Disease (PD)...Read more


Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

June 20
Last Trade: 1.17 -0.10 -7.89

ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it has received its European Union Medical Device Regulation (EU MDR) certificate and CE Mark certification for four of its products. The four products –...Read more


Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

June 20
Last Trade: 1.89 0.79 71.82

HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No 12,011,591 relating to the Company’s non-invasive Deep Intracranial Frequency Stimulation (DIFS®) medical device for the treatment of Alzheimer’s and other dementia-related brain diseases.  The newly issued...Read more


Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial

June 20
Last Trade: 1.02 -0.005 -0.49

Following FDA Approval to Commence the Clinical Trial, an Official Site Initiation Has Taken Place as Preparation for Patient Enrollment Advances Multiple Robotic Systems Already Received by the Site to Allow Inventory Readiness in Support of Trial BRAINTREE, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced its agreement with Brigham and Women’s Hospital (BWH), a leading academic medical center...Read more


Allurion Technologies Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss

June 20
Last Trade: 2.25 -0.35 -13.46

Patients gained an average of 5.6% in lean body mass during the Allurion Program Separate studies of patients on GLP-1 therapy report an average lean mass loss of 11%1 NATICK, Mass. / Jun 20, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at...Read more


First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion

June 20
Last Trade: 1.32 0.04 3.12

Reminder: Management “CEO Chat” with Zacks Small-Cap Research Analyst Begins Today at 11 a.m. Eastern Time BURLINGTON, Mass. / Jun 20, 2024 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the...Read more


Theralase Technologies: Rutherrin Repurposes Non-Cancer Drugs for Cancer Therapy

June 20
Last Trade: 0.18 -0.005 -2.70

TORONTO, ON / ACCESSWIRE / June 20, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead...Read more


Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

June 20
Last Trade: 201.49 2.18 1.09

Following a successful limited market release, the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now fully available with Dexcom G6 and Abbott FreeStyle Libre 2 Plus in these countries ACTON, Mass. / Jun 20, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5, compatible...Read more


Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates

June 20
Last Trade: 201.49 2.18 1.09

Omnipod 5, the world’s first tubeless automated insulin delivery (AID) system integrated with Dexcom G6, is now available in France Full commercial launch of Omnipod 5 with Dexcom G7 integration has commenced in the U.S. Omnipod 5 App for iPhone begins limited market release in the U.S. ACTON, Mass. / Jun 20, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump...Read more


Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer

June 20
Last Trade: 42.93 0.35 0.82

SAN DIEGO / Jun 20, 2024 / Business Wire / Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude “JC” Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare...Read more


Theralase Technologies: Rutherrin Demonstrates Complete Response in Lung Cancer Preclinically

June 19
Last Trade: 0.18 -0.005 -2.70

TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead drug formulation,...Read more


Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device

June 18
Last Trade: 85.86 0.36 0.42

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VASCADE MVP® XL mid-bore venous closure device. The VASCADE MVP XL system expands Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a...Read more


Milestone Scientific Receives Regulatory Approval to Market CompuFlo® Epidural System in Brazil

June 18
Last Trade: 0.69 0.02 2.99

Brazil is the 9th largest economy in the world with more than 21 million people suffering from chronic back pain An estimated 4-5 million epidural anesthesia procedures are performed annually in Brazil; potential to expand this addressable market due to CompuFlo’s technological advantages ROSELAND, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug...Read more


Theralase Technologies: Rutherrin Increases Efficacy of Immunotherapy Preclinically

June 18
Last Trade: 0.18 -0.005 -2.70

TORONTO, ON / ACCESSWIRE / June 18, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead...Read more


Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology

June 18
Last Trade: 1.88 0.02 0.80

NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is entering the next phase of its planned 510(k) submission to the FDA. The Company has successfully completed subject screening for its Pharmacokinetic (PK) Study and will begin dosing and sampling study...Read more


Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

June 18
Last Trade: 0.60 0.01 2.17

Aethlon Medical Granted Full Ethics Approval From the Human Research Ethics Committee at Central Adelaide Local Health Network for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO, June 18, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer...Read more


Boston Scientific Announces Agreement to Acquire Silk Road Medical

June 18
Last Trade: 77.32 0.32 0.42

Acquisition adds innovative technology for stroke prevention to vascular portfolio MARLBOROUGH, Mass., June 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a...Read more


Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions

June 18
Last Trade: 42.93 0.35 0.82

SAN DIEGO / Jun 18, 2024 / Business Wire / Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its schedule of presentations for the American Diabetes Association’s (ADA) 84th Scientific Sessions taking place in Orlando, Florida from June 21-24. Product Theater The Company will host a Product Theater on Saturday, June 22 from 10:15 am - 11:00 am EDT at Product Theater...Read more


Tivic Health: Christina Valauri Appointed to Board of Directors

June 18
Last Trade: 0.40 0.01 3.49

Wall Street Capital Markets Veteran and Recognized All-Star Bio-Medical Technology Analyst joins Tivic Health’s Governance Team SAN FRANCISCO / Jun 18, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to welcome Christina Valauri to its board of directors, effective July 1, 2024. Ms. Valauri has served as a...Read more


iRhythm Technologies Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation

June 17
Last Trade: 105.19 -0.18 -0.17

SAN FRANCISCO, June 17, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has successfully launched the initial phases of its previously disclosed manufacturing automation plans, marking a significant corporate milestone expected to set the stage for future growth and...Read more


New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024

June 17
Last Trade: 4.63 -0.04 -0.86

IRVINE, CA / ACCESSWIRE / June 17, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that new interim venous ulcer healing data from the VenoValve U.S. pivotal trial will be presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting (VAM2024) being held June 18-22, 2024 in Chicago, IL. The presentation,...Read more


Inspira Technologies Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

June 17
Last Trade: 1.34 -0.06 -4.29

RA'ANANA, Israel, June 17, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, is proud to announce today that the Company will present at the annual iECOs Conference in Herzliya, Israel on June 18th, 2024. The Company will present the INSPIRA™ ART100 System, recently 510(k) U.S. Food and Drug...Read more


Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

June 17
Last Trade: 3.65 0.17 4.89

EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market EluPro also granted clearance for indications beyond CIEDs, including neurostimulators and neuromodulators used for pain management, epilepsy, incontinence, and sleep apnea SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”),...Read more


Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress

June 17
Last Trade: 14.90 -0.19 -1.26

Events Include Symposium on Patient-Centric Approaches to Dry Eye, Highlighting Breakthroughs in Diagnosis, Treatment and Care VAUGHAN, Ontario / Jun 17, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society...Read more


Helius Medical Technologies Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke

June 17
Last Trade: 0.96 -0.0024 -0.25

Inclusion of the top neurorehabilitation centers REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions completes site participation enrollment for the U.S. registrational program in stroke  In Canada, an additional study on the use of Portable Neuromodulation Stimulator (PoNS®) Therapy to treat stroke has started to support Canadian reimbursement and U.S. approval for stroke  NEWTOWN, Pa.,...Read more


Avinger Announces Closing of up to $24 Million Public Offering

June 17
Last Trade: 1.90 -0.01 -0.72

$6 million upfront with up to an additional $18 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants REDWOOD CITY, CA / ACCESSWIRE / June 17, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the...Read more


Elutia Announces $13.26 Million Registered Direct Offering

June 17
Last Trade: 3.65 0.17 4.89

SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company’s Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company’s Class A common stock at a purchase price of $3.399 per...Read more


Ekso Bionics Appoints Deborah Lafer Scher to its Board of Directors

June 17
Last Trade: 1.04 0.01 0.97

Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso’s Board SAN RAFAEL, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. “We are...Read more


Join Sharps Technology’s Exclusive Live Investor Webinar and Q&A Session on June 18

June 14
Last Trade: 0.27 -0.01 -4.56

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is pleased to invite investors to a webinar on June 18, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Robert Hayes, CEO of Sharps Technology, who will share insight into the...Read more


Senseonics to Host Business Update and Analyst Event During the American Diabetes Association’s 84th Scientific Sessions

June 13
Last Trade: 0.39 0.00 0.00

GERMANTOWN, Md. / Jun 13, 2024 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a business update and analyst event during the American Diabetes Association’s 84th Scientific Sessions in Orlando, FL. Breakfast and...Read more


Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

June 13
Last Trade: 1.89 0.79 71.82

HOUSTON, TX, June 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency, a regulatory body of the Brazilian government responsible for approving new drugs and medical devices. Mark White, CEO of Nexalin Technology,...Read more


Movano Health Applies Advanced AI through Deep Learning to Deliver Improved Accuracy of Heart Rate in Motion

June 13
Last Trade: 0.38 -0.73 -65.87

Enhancements address significant clinical enterprise need in wearables for a variety of healthcare applications PLEASANTON, Calif., June 13, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced major advances in the accuracy of its heart rate in motion algorithm following the implementation of deep learning into the processing. The Company recently released an engineering accuracy study directed by Movano Health...Read more


Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant

June 13
Last Trade: 1.25 0.00 0.00

NPM-119 is being studied to address medication non-adherence and potentially improve tolerability issues associated with oral and injectable type 2 diabetes medications, by providing long-term therapeutic delivery of exenatide for six months Study will represent first clinical application of NanoPortal™, the company’s proprietary, implant platform technology ALAMEDA, Calif. / Jun 13, 2024 / Business Wire / Vivani Medical, Inc....Read more


PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

June 13
Last Trade: 0.84 -0.01 -1.59

First patients enrolled on the Veris Cancer Care Platform NEW YORK, June 13, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris and The Ohio State University...Read more


CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union

June 13
Last Trade: 0.80 0.0092 1.16

PRINCETON, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the launch and immediate availability of its PuriFi™ hemoperfusion machine in the E.U., following approval and certification under the E.U. Medical Device...Read more


Theralase Technologies: Rutherrin(R) Increases Efficacy of Chemotherapy

June 12
Last Trade: 0.18 -0.005 -2.70

TORONTO, ON / ACCESSWIRE / June 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead...Read more


Biotricity Launches Direct-to-Consumer Heart Health Screening Service, HeartSecure, Making Heart Health Services Accessible in Response to the #1 Global Killer, Poising Company to Access the Growing Home Diagnostics Market

June 12
Last Trade: 0.92 -0.07 -7.45

REDWOOD CITY, CA / ACCESSWIRE / June 12, 2024 / Biotricity Inc. (NASDAQ:BTCY), a forerunning Technology-as-a-Service (TaaS) company committed to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, today announces the highly anticipated launch of its direct-to-consumer heart health screening program, HeartSecure. Someone in the world dies of cardiovascular disease (CVD) every 1.5 seconds. In the...Read more


RevelAi Health and Zimmer Biomet Announce Exclusive Multi-Year Co-Marketing Agreement to Advance Value-Based Care and Health Equity through AI-Powered Technology

June 12
Last Trade: 106.85 0.60 0.56

DURHAM, N.C. and WARSAW, Ind., June 12, 2024 /PRNewswire/ -- RevelAi Health and Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a multi-year co-marketing agreement to commercialize generative artificial intelligence (AI)-powered engagement solutions that advance value-based orthopedic care and health equity. During the multi-year agreement, Zimmer Biomet will commercialize RevelAi...Read more


Positive Data from IceCure Medical's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function

June 12
Last Trade: 0.73 -0.02 -2.07

ICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors with 89.5% recurrence-free rate More data is expected in the fourth quarter of 2024, including data on patients with an average follow up of approximately 3 years  $6.92 billion global kidney cancer treatment market in 2024 expected to reach $8.78 billion by 2029—ProSense® is approved for the...Read more


Smith+Nephew personalizes robotic-assisted surgery for patients and surgeons with launch of CORIOGRAPH™ Pre-Operative Planning and Modeling Services exclusively for the CORI™ Surgical System

June 12
Last Trade: 25.36 0.11 0.44

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, providing an unparalleled, personalized solution for surgeons and patients across partial and total knee arthroplasty procedures. It is exclusively for use with the CORI Surgical System - the only orthopaedic robotic-assisted system to offer either intraoperative image-free...Read more


Accuray Announces Approval of the Accuray Precision® Treatment Planning System by China's National Medical Products Administration

June 12
Last Trade: 1.92 0.09 4.64

MADISON, Wis., June 12, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the Accuray Precision® Treatment Planning System (TPS) has been approved by the Chinese National Medical Products Administration (NMPA). The Accuray Precision TPS is now available for use with the CNNC-Accuray joint venture Tomo® C radiation therapy system and in combination, will provide medical care teams...Read more


Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

June 12
Last Trade: 2.24 -0.14 -5.73

Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos’ Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit Private Placement Investment Sponsored by Seneca Partners, Who Will Also Provide General Management Advisory Services to Fuel Growth Prospects LITTLETON, Colo., June 12, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a...Read more


Nevro to Present at Truist Securities MedTech Conference

June 11
Last Trade: 8.91 0.31 3.61

REDWOOD CITY, Calif., June 11, 2024  /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in a "fireside chat" (question-and-answer) session at the Truist Securities MedTech Conference on Tuesday, June 18, 2024, beginning at approximately 8:40 am EDT. A...Read more


NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America

June 11
Last Trade: 2.24 0.17 8.21

LANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the first product to be distributed under its recently formed partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health....Read more


Allurion Technologies Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery

June 11
Last Trade: 2.25 -0.35 -13.46

New data show 22.1% weight loss at one year with consecutive Allurion Balloons, approaching weight loss surgery outcomes NATICK, Mass. / Jun 11, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS) taking place in San Diego, California, June 9-13,...Read more


Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)

June 11
Last Trade: 1.08 -0.05 -4.42

Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annually through 20301 PITTSBURGH, June 11, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics,...Read more


Meihua International Medical Technologies to Present at the Sidoti Small Cap Conference and Update Investors at the Emerging Growth Conference on June 13, 2024

June 11
Last Trade: 0.82 -0.02 -2.41

YANGZHOU, China, June 11, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, is pleased to announce that its management team will present and host one-on-one meetings with investors at the Sidoti Small Cap Conference, and will provide an update at the...Read more


Owlet Expands Global Footprint with Launch of Medically-Certified Dream Sock™ in the UK and Across Europe

June 11
Last Trade: 4.50 0.14 3.21

LEHI, Utah / Jun 11, 2024 / Business Wire / Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today announces the UK and European launch of Dream Sock, a smart baby monitor with live health readings and notifications for healthy infants between 0-18 months and 2.5-13.6 kg. This innovative medical device provides parents with real-time health and vital information, offering unparalleled peace of...Read more


Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

June 11
Last Trade: 2.40 0.00 0.00

WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger...Read more


Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

June 10
Last Trade: 10.08 -0.57 -5.35

SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates featuring the Company’s alpha-particle radiopharmaceuticals at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting, that was held on June...Read more


BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

June 10
Last Trade: 0.33 -0.14 -29.72

Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer.   Personal Bio, Ferdinand Groenewald, age 39 Ferdinand Groenewald is a certified...Read more


ResMed: PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

June 10
Last Trade: 208.90 -4.37 -2.05

SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. Held in Houston, the event brought together scientific and medical experts focused on sleep health. From exploration into the prevalence of...Read more


MIT Selects Movano Health for Groundbreaking Study on Long COVID and Chronic Lyme Disease

June 10
Last Trade: 0.38 -0.73 -65.87

Pioneering partnership advances innovative health monitoring, setting the stage for future enterprise opportunities. PLEASANTON, Calif., June 10, 2024 /PRNewswire/ -- In a strategic move that could reshape the understanding of long COVID and chronic Lyme disease, the Massachusetts Institute of Technology (MIT) has forged a partnership with Movano Health for its MAESTRO study to harness the medical grade continuous health monitoring...Read more


Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems

June 10
Last Trade: 105.38 -1.19 -1.12

Abbott's consumer biowearable, Lingo™, is designed for general consumers who are looking to improve their overall health and wellness Libre Rio™ is designed for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications Both products are based on FreeStyle Libre® sensing technology, the world's most widely used1 continuous glucose monitoring (CGM) systems, pioneered by Abbott...Read more


BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression

June 10
Last Trade: 6.17 -0.06 -0.96

BURLINGTON, Mass. and JERUSALEM, June 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the initiation of a prospective, randomized, controlled, multicenter clinical trial evaluating an accelerated treatment protocol for the Company’s proprietary Deep Transcranial Magnetic...Read more


Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States

June 10
Last Trade: 14.90 -0.19 -1.26

VAUGHAN, Ontario / Jun 10, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material infused with ProBalance Technology™ and the company’s proprietary OpticAlign® design, INFUSE for...Read more


Theralase Technologies: Ruvidar(TM) Enhances Efficacy of Cancer Drug

June 10
Last Trade: 0.18 -0.005 -2.70

TORONTO, ON / ACCESSWIRE / June 10, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead compound, RuvidarTM, when combined...Read more


Therma Bright Closes $854,500 First Tranche of Non-Brokered Private Placement

June 10
Last Trade: 0.02 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - June 10, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it has completed the first tranche ("First Tranche") of its previously announced non-brokered private placement (the "Offering"). Under the First Tranche, Therma...Read more


Asensus Surgical Announces Signing of Definitive Merger Agreement with KARL STORZ

June 7
Last Trade: 0.33 0.0042 1.30

KARL STORZ to acquire Asensus for $0.35 per share in cash Creating a leading surgical robotics division within KARL STORZ RESEARCH TRIANGLE PARK, N.C., June 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus Surgical” or “Asensus”), a global leader of innovative digital solutions for the operating room, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”)...Read more


Cutera® Announces AviClear® Investor Webinar

June 7
Last Trade: 1.56 -0.10 -6.06

BRISBANE, Calif. / Jun 07, 2024 / Business Wire / CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will hold an investor webinar at 11 a.m. PDT on June 20, 2024, to present an overview of AviClear, the first FDA-cleared energy device for the long-term treatment of mild, moderate, and severe inflammatory acne. The webinar will include a review of clinical data, market...Read more


STRATA Skin Sciences’ TheraClear®X Acne Therapy System Found to be Safe and Effective for Acne Lesions Across All Fitzpatrick Skin Types with Favorable Tolerability and Patient Satisfaction as Published in Peer Reviewed Journal

June 7
Last Trade: 3.08 -0.12 -3.75

HORSHAM, Pa., June 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announces the publication of a clinical study titled, " A 7-Week Open-Label Trial Evaluating the Safety and Efficacy of TheraClear®X for Mitigating...Read more


Baxter to Present at Goldman Sachs 45th Annual Global Healthcare Conference

June 6
Last Trade: 34.13 0.12 0.35

DEERFIELD, Ill. / Jun 06, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 8:40 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Monday,...Read more


Harvard Bioscience to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024

June 6
Last Trade: 2.87 0.00 0.00

HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14th Annual East Coast IDEAS Conference at the Jay Conference Center – Bryant Park in New York City on June 12, 2024. The Company’s presentation is scheduled for 2:45-3:20 PM ET on June 12th. The...Read more


Integer to Present at 2024 Truist Securities MedTech Conference on June 18

June 6
Last Trade: 115.78 0.03 0.03

PLANO, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced participation at the 2024 Truist Securities MedTech Conference, to be held June 17 – 18, 2024, in Boston. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present as part of a fireside chat on Tuesday, June 18, at...Read more


Spectral AI Reaches 50% Enrollment at Burn Centers for U.S. Pivotal Burn Study

June 6
Last Trade: 1.63 0.04 2.51

DALLAS, June 06, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has achieved 50% clinical trial site enrollment at burn centers for its 2024 pivotal study designed to validate the algorithm used by its DeepView™ System for burn...Read more


Masimo to Present in Goldman Sachs 45th Annual Global Healthcare Conference

June 6
Last Trade: 132.24 1.85 1.42

IRVINE, Calif. / Jun 06, 2024 / Business Wire / Masimo (NASDAQ: MASI) today announced that its management will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq:...Read more


LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients

June 6
Last Trade: 56.07 0.44 0.79

Primary endpoint did not achieve statistical significance in unipolar patient cohort Statistically significant and clinically meaningful benefits seen in select secondary endpoints; no safety concerns identified LONDON / Jun 06, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study, assessing...Read more


Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase

June 6
Last Trade: 0.21 -0.01 -5.05

MINNEAPOLIS, June 06, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc.  (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, today announced the extension of its pilot phase under its previously announced supply and collaboration agreement with DaVita Inc. (NYSE: DVA) until August 31, 2024. This program aims to pilot Aquadex® ultrafiltration therapy for adult patients suffering...Read more


Theralase Technologies Successfully Destroys Lung Cancer

June 6
Last Trade: 0.18 -0.005 -2.70

TORONTO, ON / ACCESSWIRE / June 6, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and/or radiation activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead compound, RuvidarTM, combined with transferrin to...Read more


electroCore Announces Closing of $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules

June 6
Last Trade: 6.00 -0.11 -1.80

ROCKAWAY, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced the closing of its previously announced registered direct offering of 225,000 registered pre-funded warrants to purchase shares of common stock (the “registered pre-funded warrants”) to an institutional accredited investor; the concurrent...Read more


Myomo to Present at the Sidoti Virtual Investor Conference on June 12-13, 2024

June 5
Last Trade: 3.15 0.01 0.32

BOSTON / Jun 05, 2024 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, chairman and chief executive officer and David Henry, chief financial officer, will present and host one-on-one meetings with investors at the Sidoti Virtual...Read more


AVITA Medical Achieves Milestone with First Case Using RECELL GO

June 5
Last Trade: 8.36 0.06 0.72

VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the Joseph M. Still Burn Center at Doctors Hospital of Augusta is the first U.S. burn center to treat a patient using its RECELL GO™ System. Recently FDA-approved, RECELL GO is a...Read more


SI-BONE To Present at Truist Securities 2024 MedTech Conference on June 18, 2024

June 5
Last Trade: 12.21 0.00 0.00

SANTA CLARA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 Truist Securities MedTech Conference in Boston. Management will be hosting a fireside chat on Tuesday, June 18, at 3:40 p.m. Eastern Time / 12:40 p.m. Pacific Time. Investors...Read more


Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference

June 5
Last Trade: 13.19 -0.22 -1.64

BILLERICA, Mass. / Jun 05, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs 45th Annual Global Healthcare Conference. Toloue will speak alongside Chief Financial Officer Vandana Sriram in a fireside chat presentation on Wednesday, June 12, 2024, at 2:40 p.m....Read more


Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR

June 5
Last Trade: 90.36 1.52 1.71

NEW YORK / Jun 05, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient’s annulus...Read more


Inspira Technologies to Exhibit the FDA Cleared INSPIRA™ ART100 System at a World-Renowned Event in the Sector

June 5
Last Trade: 1.34 -0.06 -4.29

The event is an opportunity to present and demonstrate new products and technologies to potential customers and strategic partners RA'ANANA, Israel, June 5, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, is proud to announce plans to exhibit the INSPIRA™ ART100 System, recently cleared by the U.S. Food...Read more


Intuitive Announces FDA Clearance of Revised da Vinci Xi and X Labeling on Radical Prostatectomy

June 5
Last Trade: 431.46 -1.09 -0.25

SUNNYVALE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared a labeling revision for da Vinci X and Xi specific to radical prostatectomy. This clearance was based on real-world evidence (RWE) collected from 2007 to 2014 that demonstrates overall five-...Read more


Nano-X Imaging Launches Artificial Intelligence Functionality in Second Opinions Platform

June 5
Last Trade: 6.92 0.19 2.82

Nanox integrates FDA-cleared population health AI solutions into its Second Opinions service New AI capabilities available to patients who submit chest and abdominal CT scans for second opinions Offering the power of Artificial Intelligence to their second opinion CT report to promote early detection of chronic conditions PETACH TIKVA, Israel, June 05, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,”...Read more


Envoy Medical: Newly Published Peer-Reviewed Article Highlights Advances in Fully Implanted Cochlear Implant Technology

June 5
Last Trade: 2.40 0.00 0.00

Envoy Medical in Position to Leverage its Sensor Technology WHITE BEAR LAKE, MN, June 05, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH) today highlighted a recently published article in the Current Otorhinolaryngology Reports. The article, titled, “Fully Implanted Cochlear Implants,” was authored by Dr. Eric Babajanian, Dr. James Dornhoffer, and Dr. Colin Driscoll from Mayo Clinic in Rochester,...Read more


Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion

June 5
Last Trade: 2.65 0.30 12.77

The companies, KORU Medical, manufacturer of the proprietary, large-volume, Freedom Infusion System (the “Freedom System”) and SCHOTT Pharma, manufacturer of SCHOTT TOPPAC® prefillable polymer syringes (PFS), intend to collaborate on optimization of drug delivery in the large volume subcutaneous infusion market. When combined with pharma therapies, the joint offering will optimize the ability to administer large volumes of medication...Read more


Penumbra to Present at the Truist Securities MedTech Conference

June 4
Last Trade: 177.74 2.29 1.31

ALAMEDA, Calif., June 4, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024. Event: Truist Securities MedTech Conference Date: Tuesday, June 18, 2024 Time: 10:05am ET/7:05am PT A webcast of the presentation can be accessed on the "Events and...Read more


Lifeward to Present at Sidoti Virtual Investor Conference on June 12

June 4
Last Trade: 4.10 0.00 0.00

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 04, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced that Larry Jasinski, Chief Executive Officer,...Read more


InfuSystem to Present at Sidoti Small Cap Conference on June 12, 2024

June 4
Last Trade: 6.59 0.17 2.65

Investor Presentation to be held at 8:30 a.m. Eastern Time ROCHESTER HILLS, Mich. / Jun 04, 2024 / Business Wire / InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that Richard DiIorio, Chief Executive Officer, Barry Steele, Chief Financial...Read more


Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

June 4
Last Trade: 1.02 -0.005 -0.49

HINGHAM, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,566,669 shares of the Company’s common stock at a purchase price of $1.50 per share of common stock . In addition, in a concurrent private placement, the Company has issued unregistered series F...Read more


Azenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease and Ulcerative Colitis Clinical Research

June 4
Last Trade: 56.64 -0.09 -0.16

Azenta has been Selected by the Crohn's & Colitis Foundation as its Sample Management Services Provider for its Inflammatory Bowel Disease (IBD) CAPTURE and SIRQC Clinical Registries BURLINGTON, Mass., June 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Crohn's & Colitis Foundation (the "Foundation") as its sample management services provider for two of its large-scale...Read more


iRhythm Technologies to Present at the 2024 Truist Securities MedTech Conference

June 4
Last Trade: 105.19 -0.18 -0.17

SAN FRANCISCO, June 04, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Truist Securities MedTech Conference. iRhythm’s management is scheduled to participate in a fireside chat on Tuesday, June 18, at 9:20 a.m. Eastern Time....Read more


KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic

June 4
Last Trade: 2.65 0.30 12.77

MAHWAH, N.J. / Jun 04, 2024 / Business Wire / KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical company to initiate a feasibility study with KORU Medical’s Freedom Infusion...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Medical Device Gainers

 
CompanyChangeLast Trade
Repligen 2.89 2.41 $122.89
Penumbra 2.29 1.31 $177.74
Insulet 2.18 1.09 $201.49
Inspire Medical Systems 1.98 1.18 $169.69
Masimo 1.85 1.42 $132.24
Edwards Lifesciences 1.52 1.71 $90.36
Atrion 1.25 0.28 $451.25
Medtronic 0.93 1.16 $81.10
Vapotherm 0.83 65.35 $2.10
Nexalin Technology 0.79 71.82 $1.89
Glaukos 0.63 0.56 $112.29
Zimmer Biomet 0.60 0.56 $106.85
Teleflex 0.57 0.28 $202.66
LeMaitre Vascular 0.50 0.62 $81.10
Outset Medical 0.50 13.81 $4.08

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB